

REMARKS

The amendment to the specification is made to more clearly describe the figures and to identify the sequences disclosed in the application as originally filed. The amendment to the drawings is made to replace the originally submitted Figure 2A which contained a minor typographical error in which a colon was erroneously placed in the sequence. The original Figure 2A also distinguished certain sequences that were not assigned separate sequence identifiers. New Figure 2A removes the colon and provides sequence identification numbers to clearly identify these sequences.

The foregoing amendments do not introduce new matter and are supported by the application as originally filed. Specifically, support for these amendments can be found in the specification at page 7, lines 27 –29, and in Figure 1 of the drawings. Entry of the foregoing amendment is respectfully requested.

Enclosed herewith is a marked-up version of the changes made to the specification by this amendment. The enclosed page is captioned "**Version with markings to show changes made.**"


Favorable action on the merits is earnestly solicited.

Respectfully submitted,
DELTAGEN, INC.

740 Bay Road
Redwood City, CA 94063
Tel. (650) 569-5172
Fax. (650) 569-5280


Marlette A. Lapiz, Reg. No. 44,202

I certify that this amendment and enclosures are being deposited with the U. S. Postal Service with sufficient postage as first class mail in an envelope addressed to The Commissioner for Patents, Washington, D.C. 20231, on October 24, 2001.
 also transmitted by facsimile.



Gayle D. Peterson

Version with markings to show changes made

In the Specification:

Figure 2A-2B shows design of the targeting construct used to disrupt anaphylatoxin C3a receptor genes. Figure 2A-2B shows the design of the targeting construct used to disrupt anaphylatoxin C3a receptor genes. Figure 2A shows the anaphylatoxin C3a target gene sequence (SEQ ID NO:1), identifying the sequence to be deleted (SEQ ID NO:5) and its flanking sequences (SEQ ID NO:6 and SEQ ID NO:7). Figure 2B shows the sequences identified as SEQ ID NO:3 and SEQ ID NO:4, which were used as the targeting arms (homologous sequences) in the anaphylatoxin C3a receptor targeting construct